Literature DB >> 20031633

Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy.

Rita Wen Kaspar1, Hugh D Allen, Will C Ray, Carlos E Alvarez, John T Kissel, Alan Pestronk, Robert B Weiss, Kevin M Flanigan, Jerry R Mendell, Federica Montanaro.   

Abstract

BACKGROUND: Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy often result from deletion mutations in the dystrophin gene that may lead to expression of an altered dystrophin protein in cardiac muscle. Cardiac involvement is present in approximately 70% of BMD and all X-linked dilated cardiomyopathy cases. To date, the timing of cardiomyopathy development remains unpredictable. We analyzed 78 BMD and X-linked dilated cardiomyopathy patients with common deletion mutations predicted to alter the dystrophin protein and correlated their mutations to cardiomyopathy age of onset. This approach was chosen to connect dystrophin structure with function in the heart. METHODS AND
RESULTS: Detailed cardiac information was collected for BMD and X-linked dilated cardiomyopathy patients with defined dystrophin gene deletion mutations. Patients were grouped based on the dystrophin protein domain affected by the deletion. Deletions affecting the amino-terminal domain are associated with early-onset dilated cardiomyopathy (DCM; mid-20s), whereas deletions removing part of the rod domain and hinge 3 have a later-onset DCM (mid-40s). Further, we modeled the effects of the most common mutations occurring in the rod domain on the overall structure of the dystrophin protein. By combining genetic and protein information, this analysis revealed a strong correlation between specific protein structural modifications and DCM age of onset.
CONCLUSIONS: We identified specific regions of the dystrophin gene that when mutated predispose BMD patients to early-onset DCM. In addition, we propose that some mutations lead to early-onset DCM by specific alterations in protein folding. These findings have potential implications for early intervention in the cardiac care of BMD patients and for therapeutic approaches that target the heart in dystrophinopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031633      PMCID: PMC2826810          DOI: 10.1161/CIRCGENETICS.109.867242

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  25 in total

1.  107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

Authors:  K Bushby; F Muntoni; J P Bourke
Journal:  Neuromuscul Disord       Date:  2003-02       Impact factor: 4.296

2.  Structural predictions for the central domain of dystrophin.

Authors:  R A Cross; M Stewart; J Kendrick-Jones
Journal:  FEBS Lett       Date:  1990-03-12       Impact factor: 4.124

Review 3.  Genetics of Duchenne muscular dystrophy.

Authors:  R G Worton; M W Thompson
Journal:  Annu Rev Genet       Date:  1988       Impact factor: 16.830

4.  Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy.

Authors:  F Muntoni; M Cau; A Ganau; R Congiu; G Arvedi; A Mateddu; M G Marrosu; C Cianchetti; G Realdi; A Cao
Journal:  N Engl J Med       Date:  1993-09-23       Impact factor: 91.245

Review 5.  Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy.

Authors:  E Arbustini; M Diegoli; P Morbini; B Dal Bello; N Banchieri; A Pilotto; F Magani; M Grasso; J Narula; A Gavazzi; M Viganò; L Tavazzi
Journal:  J Am Coll Cardiol       Date:  2000-06       Impact factor: 24.094

6.  Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years.

Authors:  M Yazaki; K Yoshida; A Nakamura; J Koyama; T Nanba; N Ohori; S Ikeda
Journal:  Eur Neurol       Date:  1999       Impact factor: 1.710

7.  Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.

Authors:  Scott Q Harper; Michael A Hauser; Christiana DelloRusso; Dongsheng Duan; Robert W Crawford; Stephanie F Phelps; Hollie A Harper; Ann S Robinson; John F Engelhardt; Susan V Brooks; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

8.  Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.

Authors:  M H Brooke; G M Fenichel; R C Griggs; J R Mendell; R Moxley; J P Miller; M A Province
Journal:  Muscle Nerve       Date:  1983-02       Impact factor: 3.217

9.  Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice.

Authors:  Brian Bostick; Yongping Yue; Chun Long; Nate Marschalk; Deborah M Fine; Jing Chen; Dongsheng Duan
Journal:  Mol Ther       Date:  2008-12-09       Impact factor: 11.454

10.  Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies.

Authors:  A H Beggs; E P Hoffman; J R Snyder; K Arahata; L Specht; F Shapiro; C Angelini; H Sugita; L M Kunkel
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

View more
  52 in total

1.  Novel mutation in spectrin-like repeat 1 of dystrophin central domain causes protein misfolding and mild Becker muscular dystrophy.

Authors:  Gyula Acsadi; Steven A Moore; Angélique Chéron; Olivier Delalande; Lindsey Bennett; William Kupsky; Mohammad El-Baba; Elisabeth Le Rumeur; Jean-François Hubert
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

Review 2.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

Review 3.  Cardiomyopathy in becker muscular dystrophy: Overview.

Authors:  Rady Ho; My-Le Nguyen; Paul Mather
Journal:  World J Cardiol       Date:  2016-06-26

4.  AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice.

Authors:  Brian Bostick; Jin-Hong Shin; Yongping Yue; Dongsheng Duan
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

5.  Feasibility and Reproducibility of Echocardiographic Measures in Children with Muscular Dystrophies.

Authors:  Christopher F Spurney; Francis M McCaffrey; Avital Cnaan; Lauren P Morgenroth; Sunil J Ghelani; Heather Gordish-Dressman; Adrienne Arrieta; Anne M Connolly; Timothy E Lotze; Craig M McDonald; Robert T Leshner; Paula R Clemens
Journal:  J Am Soc Echocardiogr       Date:  2015-04-21       Impact factor: 5.251

Review 6.  Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.

Authors:  Joyce C Ohiri; Elizabeth M McNally
Journal:  Heart Fail Clin       Date:  2018-04       Impact factor: 3.179

7.  Clinical Utility Gene Card for: Becker muscular dystrophy.

Authors:  David Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-02-21       Impact factor: 4.246

8.  Cardiac-Specific Expression of ΔH2-R15 Mini-Dystrophin Normalized All Electrocardiogram Abnormalities and the End-Diastolic Volume in a 23-Month-Old Mouse Model of Duchenne Dilated Cardiomyopathy.

Authors:  Nalinda B Wasala; Jin-Hong Shin; Yi Lai; Yongping Yue; Federica Montanaro; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2018-03-22       Impact factor: 5.695

Review 9.  The Dystrophin Complex: Structure, Function, and Implications for Therapy.

Authors:  Quan Q Gao; Elizabeth M McNally
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

10.  A case of Becker muscular dystrophy with early manifestation of cardiomyopathy.

Authors:  Ki Hyun Doo; Hye Won Ryu; Seung Soo Kim; Byung Chan Lim; Hui Hwang; Ki Joong Kim; Yong Seung Hwang; Jong-Hee Chae
Journal:  Korean J Pediatr       Date:  2012-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.